Pharming Group (PHAR) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Pharming Group N.V. relies on stable demand within the sovereign cycle, which renders the asset defensive during a recession. The company delegates capital-intensive production and testing to partners, maintaining a lean workforce. The current EV/EBITDA multiple valuation on the GURU.Markets chart shows that 18.82 is the current metric. Meanwhile, drug filling and raw material purification are outsourced to external CMOs.
pharming.com - analytical breakdowns and key metrics (PHAR)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
- business earnings and investment ratios data:
PHAR - Net Profit|Expected Profit Pharming Group N.V.|PHAR - Company Value to Net Income|Future Price to Earnings Pharming Group N.V.|PHAR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Pharming Corp|PHAR - Operating income before deduction of amortization|Earnings per share for the last twelve months Pharming Group|PHAR - Earnings per share for the last 12 months|Quarterly EPS earnings growth pharming.com|PHAR - Net earnings per share change in current year|Expected earnings per share growth for next year Pharming Group N.V.
Initial company analysis:PHAR (Pharming)
Fundamental asset screening requires an analysis of enterprise value inclusive of net debt relative to operating profit before depreciation and amortization. The current EV/EBITDA multiple valuation measures the capital payback period, while the stable cash flow from orphan drug sales at Pharming Group N.V. (PHAR) minimizes excessive leverage risks and ensures sustainable funding for new clinical trials.
Direct competitors
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio DNTH|PHVS: EV/EBITDA Multiple|AbCellera - Business Value to Operating Income Before Depreciation|TRML (Tourmaline Bio) - EV/EBITDA Multiple|EV/EBITDA Multiple Precigen Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nektar (NKTR)|UPB (Upstream Pharma) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zenas Biopharma Inc ZBIO|IMNM - Enterprise Value to EBITDA Ratio|Gossamer Bio - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio KalVista Pharma KALV|Septerna Corp (SEPN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation PVLA|SVRA (Savara Inc.) - EV/EBITDA Multiple|RIGL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio ANAB (AnaptysBio)|ATXS (Astria Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ENGN (enGene Bio)|Enterprise Value to EBITDA Multiple rapt.com|JBIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ACRS (aclaristx.com)|Kyverna Therapeutics, Inc. (KYTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Tiziana Life Sciences Ltd. (TLSA)|Enterprise Value to EBITDA Ratio CABA|EV/EBITDA Multiple Ventyx Biosciences, Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Theratechnologies Inc. (THTX)|AVTX: Company Value to Operating Income Before Depreciation Ratio|Eledon Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation AGEN|CLYM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ZURA (zurabio.com) - Enterprise Value to Operating Income Before Depreciation|ATYR (aTyr Pharma, Inc.) - Enterprise Value to EBITDA Ratio|ADAG - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio IMA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization STTK|Enterprise Value to EBITDA Ratio EQ (Equillium, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio connectbiopharm.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunic IMUX|ATRA (Atara Biotherapeutics, Inc.) - Company Value to Operating Income Before Depreciation Ratio|InflaRx GmbH - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation XFOR (X4 Pharmaceuticals Inc.)|ACET: EV/EBITDA Multiple|Celularity (CELU) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio, Inc.|BRNS: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kezar Life Sciences, Inc. (KZR)|SABS: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AKTX (Akari Therapeutics plc)|Business Value to Operating Income Before Depreciation ENLV|Q32 Bio Corp - EV/EBITDA Multiple|GOVX - EV/EBITDA Multiple|Edesa Biotech (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|iBio Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Carisma Therapeutics Inc|Enterprise Value to EBITDA Ratio XTL Bio (XTLB)|EV/EBITDA Multiple BOLT|EV/EBITDA Multiple hcwbiologics.com (HCWB)|Aptevo Therapeutics Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation AIM|Aditxt Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio GRI Bio Corporation GRI|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio reshapelifesciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to EBITDA Ratio Indaptus Therapeutics Inc (INDP)|Enterprise Value to EBITDA Ratio SCNI (Scinai)|EV/EBITDA Multiple calcimedica.com (CALI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK: Enterprise Value to Operating Income Before Depreciation|HOOKIPA - EV/EBITDA Multiple|Company Value to EBITDA IGM Biosciences, Inc.|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OCEA (Ocean Biomedical Corp)|TCBP (TC Biopharm) - EV/EBITDA Multiple|THRD: Business Value to Operating Income Before Depreciation
